Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV
Year: 2024
Type: article
Study design: Observational Study
Abstract: Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.
Source: AIDS
Authors: Arthur T. Johnson, Taolo Ntloedibe, Jose Euberto Mendez Reyes, Mogomotsi S. Matshaba, Scott L. Dryden-Peterson, Elizabeth Y. Chiao
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation, Botswana CASCADE Clinical Trials Site, Harvard University Center for AIDS Research, Dana-Farber/Harvard Cancer Center, Integrated Networks of Scholars in Global Health Research Training (INSIGHT) Program
OpenAlex ID: W4400092452